Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume 48, Issue 4, Pages 557-561
Publisher
Springer Nature
Online
2012-09-10
DOI
10.1038/bmt.2012.170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution
- (2011) D. C. Seldin et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis
- (2011) H. Landau et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
- (2011) Giovanni Palladini et al. ANNALS OF HEMATOLOGY
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
- (2011) M. T. Cibeira et al. BLOOD
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- Differentiation of human peripheral blood V 1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells
- (2011) D. V. Correia et al. BLOOD
- Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with al amyloidosis
- (2011) Edwin A. Burgstaler et al. JOURNAL OF CLINICAL APHERESIS
- Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy
- (2011) A. D. Cohen et al. Hematology-American Society of Hematology Education Program
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
- (2010) P. Moreau et al. BLOOD
- Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
- (2010) S. Dietrich et al. BLOOD
- Pitfalls in the Diagnosis of Primary Amyloidosis
- (2010) Cheng E. Chee et al. Clinical Lymphoma Myeloma & Leukemia
- Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
- (2010) Morie A. Gertz et al. LEUKEMIA & LYMPHOMA
- Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score
- (2010) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
- Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens
- (2009) J. A. Vrana et al. BLOOD
- Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative
- (2009) Morie A. Gertz et al. MAYO CLINIC PROCEEDINGS
- Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
- (2008) D. Lebovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis
- (2008) Morie Gertz et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More